Weycker, D; Danel, A; Marciniak, A; Bendall, K; Lipsitz, M; Pettengell, R
(2012)
Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice.
BMC CANCER, 12.
p. 362.
ISSN 1471-2407
https://doi.org/10.1186/1471-2407-12-362
SGUL Authors: Pettengell, Ruth
|
["document_typename_application/pdf; charset=binary" not defined]
Published Version
Download (216kB) | Preview |
Abstract
Background: Economic implications of chemotherapy-induced febrile neutropenia (FN) in European and Australian clinical practice are largely unknown. Methods: Data were obtained from a European (97%) and Australian (3%) observational study of patients with non-Hodgkin’s lymphoma (NHL) receiving CHOP (±rituximab) chemotherapy. For each patient, each cycle of chemotherapy within the course, and each occurrence of FN within cycles, was identified. Patients developing FN in a given cycle (“FN patients”), starting with the first, were matched to those who did not develop FN in that cycle (“comparison patients”), irrespective of subsequent FN events. FN-related healthcare costs (£2010) were tallied for the initial FN event as well as follow-on care and FN events in subsequent cycles. Results: Mean total cost was £5776 (95%CI £4928-£6713) higher for FN patients (n = 295) versus comparison patients, comprising £4051 (£3633-£4485) for the initial event and a difference of £1725 (£978-£2498) in subsequent cycles. Among FN patients requiring inpatient care (76% of all FN patients), mean total cost was higher by £7259 (£6327-£8205), comprising £5281 (£4810-£5774) for the initial hospitalization and a difference of £1978 (£1262-£2801) in subsequent cycles. Conclusions: Cost of chemotherapy-induced FN among NHL patients in European and Australian clinical practice is substantial; a sizable percentage is attributable to follow-on care and subsequent FN events.
Item Type: | Article |
---|---|
Additional Information: | © 2012 Weycker et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
Keywords: | Aged, Antineoplastic Combined Chemotherapy Protocols, Australia, Europe, Female, Fever, Health Care Costs, Humans, Lymphoma, Non-Hodgkin, Male, Middle Aged, Neutropenia |
SGUL Research Institute / Research Centre: | Academic Structure > Institute of Medical, Biomedical and Allied Health Education (IMBE) Academic Structure > Institute of Medical, Biomedical and Allied Health Education (IMBE) > Centre for Clinical Education (INMECE ) |
Journal or Publication Title: | BMC CANCER |
ISSN: | 1471-2407 |
Related URLs: | |
PubMed ID: | 22913768 |
Web of Science ID: | 22913768 |
![]() ![]() |
Download EPMC Full text (PDF) |
![]() |
Download EPMC Full text (HTML) |
Go to PubMed abstract | |
URI: | https://openaccess.sgul.ac.uk/id/eprint/103227 |
Publisher's version: | https://doi.org/10.1186/1471-2407-12-362 |
Statistics
Actions (login required)
![]() |
Edit Item |